Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience Abstract #1275

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Aim(s): To evaluate the efficacy and safety of Aranoza in metastatic WD NETs
Materials and methods: We performed a prospective analysis of all pts treated with Aranoza (500 mg/m2 for 3 days every 3 weeks) at our center between July 2007 and July 2014. The median progression-free survival was calculated using Kaplan-Meier method. Treatment efficacy was evaluated according to RECIST
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#474 Difficulties in Diagnosis and Management of Neuroendocrine Tumors of the Head and Neck: A Case Report
Introduction: Primary neuroendocrine carcinomas (NEC) are uncommon head and neck malignancies. They present with a varied histopathologic spectrum in sinonasal and other subsites.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Alla Markovich
#659 Everolimus in Patients with Previously Treated Metastatic Neuroendocrine Tumors (NETs)
Introduction: Everolimus is the standard of care in well-differentiated NETs. Previous randomized trials included patients treated with a maximum of two lines of prior chemotherapy. We evaluated everolimus in heavily pretreated patients with NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Alexander Kuzminov
#902 Chemotherapy for Advanced Neuroendocrine Tumors (NETs): Patient Selection Should be Independent of Primary Tumor Site
Introduction: Chemotherapy (CT) is used to treat patients (pts) with advanced poorly-differentiated (Pd); or well-differentiated (Wd) NETs with high-tumor burden (usually of pancreatic (pNET) origin).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Angela Lamarca
#910 Experience of Temozolomide Mono- and Combination Therapy in Advanced Neuroendocrine Tumors (NETs) in Russia
Introduction: Temozolomide (T) demonstrated promising activity in NETs in numerous phase 2 studies worldwide. But there is not enough data about its efficacy in the Russian population.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Alexander Kuzminov
#1294 The Efficacy and Safety of Sunitinib in Heavily Pretreated Patients with NETs. National Cancer Research Center Experience.
Introduction: There was done monocentral trial. 19 pts with progressive well differentiated NETs (G1,G2) were treated with sunitinib
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Anastacia Odintsova